In another randomized controlled trial, there was a significant increase in serum 25(OH)D levels (mean difference 14 ng/mL, 95% CI 5.6 to 22.4) and an associated decrease in PTH levels (mean difference −31.5 pg/mL, 95% CI −57 to −6.1) with a low incidence of hypercalcemia (up to 3%) and hyperphosphatemia (up to 7%) after NVD supplementation [129]. The gene discussed is PTH; the disease is hyperphosphatemia.